PMID- 16970949
OWN - NLM
STAT- MEDLINE
DCOM- 20071227
LR  - 20101118
IS  - 1879-1484 (Electronic)
IS  - 0021-9150 (Linking)
VI  - 194
IP  - 2
DP  - 2007 Oct
TI  - Hyperhomocysteinemia in patients with symptomatic chronic heart failure: 
      prevalence and prognostic importance--pilot study.
PG  - 408-14
AB  - BACKGROUND: Patients with chronic heart failure (CHF) may be particularly 
      susceptible to unfavorable effects of hyperhomocysteinemia (HHcy). The aim of 
      this study was to assess the prevalence of HHcy (plasma homocysteine [Hcy]>or=14 
      micromol/L) in an unselected cohort of CHF patients, its clinical determinants, 
      and prognostic implications. METHODS AND RESULTS: In 108 consecutive CHF patients 
      (81 men, age: 66+/-11 years) with mean plasma Hcy level 12.5+/-5.5 micromol/L 
      (range 2.3-28.3 micromol/L), 38 (35%) patients demonstrated HHcy. Among clinical 
      and metabolic parameters, in multivariable regression models, advanced NYHA class 
      (P<0.0001), plasma NT-proBNP (P<0.001), peak oxygen consumption (P<0.05), reduced 
      glomerular filtration rate (P<0.0001) and elevated serum uric acid (P<0.05) 
      predicted high plasma Hcy level. HHcy was related to increased mortality 
      (HR=3.26, 95% CI: 1.78-5.98, P=0.0001), also when adjusted for conventional 
      prognosticators in multivariable models (all P<0.01). In patients with HHcy, a 
      3-year survival was 37% (95% CI: 22-52%) as compared to 73% (95% CI: 63-83%) in 
      those with normal Hcy levels (P<0.0001). CONCLUSIONS: HHcy is common in CHF, is 
      related to the disease severity, depicts generalized metabolic imbalance 
      (evidenced by hyperuricaemia), and independently predicts poor long-term 
      prognosis.
FAU - Naruszewicz, Marek
AU  - Naruszewicz M
AD  - Department of Clinical Biochemistry and Laboratory Diagnostics, Pomeranian 
      Medical University, al. Powstancow Wlkp. 72, 70-111 Szczecin, Poland. 
      mnarusze@sci.pam.szczecin.pl
FAU - Jankowska, Ewa A
AU  - Jankowska EA
FAU - Zymlinski, Robert
AU  - Zymlinski R
FAU - Bukowska, Hanna
AU  - Bukowska H
FAU - Millo, Barbara
AU  - Millo B
FAU - Banasiak, Waldemar
AU  - Banasiak W
FAU - Ponikowski, Piotr
AU  - Ponikowski P
LA  - eng
PT  - Journal Article
DEP - 20060912
PL  - Ireland
TA  - Atherosclerosis
JT  - Atherosclerosis
JID - 0242543
RN  - 0 (Peptide Fragments)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
MH  - Aged
MH  - Female
MH  - Heart Failure/*blood/mortality
MH  - Humans
MH  - Hyperhomocysteinemia/*blood/epidemiology
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/blood
MH  - Peptide Fragments/blood
MH  - Pilot Projects
MH  - Poland/epidemiology
MH  - Prevalence
MH  - Prognosis
MH  - Proportional Hazards Models
EDAT- 2006/09/15 09:00
MHDA- 2007/12/28 09:00
CRDT- 2006/09/15 09:00
PHST- 2006/04/20 00:00 [received]
PHST- 2006/07/17 00:00 [revised]
PHST- 2006/08/02 00:00 [accepted]
PHST- 2006/09/15 09:00 [pubmed]
PHST- 2007/12/28 09:00 [medline]
PHST- 2006/09/15 09:00 [entrez]
AID - S0021-9150(06)00475-8 [pii]
AID - 10.1016/j.atherosclerosis.2006.08.014 [doi]
PST - ppublish
SO  - Atherosclerosis. 2007 Oct;194(2):408-14. doi: 
      10.1016/j.atherosclerosis.2006.08.014. Epub 2006 Sep 12.